type 2 diabetes semaglutide tops dulaglutide when treating patients with and CVD Semaglutide and Type 2 Diabetes:

Key Facts About Saxenda Active ingredient: Liraglutide FDA approval: For weight loss in adults and adolescents Dosing schedule: Daily injection Typical dosage: Titrates up to 3.0 mg per day Target patients: Adults with BMI 30, or 27 with related conditions

In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weekscomparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who dont tolerate GLP-1 medications well

So verlierst Du Fett und letztendlich Gewicht

Gastroenterology Research and Practice, 2013

Raises NAD+ + SAM pools drives white-adipose lipolysis